Interferon DNA polymorphism in chronic leukemia

Leuk Lymphoma. 1994 Mar;13(1-2):99-103. doi: 10.3109/10428199409051658.

Abstract

The interferon (IFN) system (alpha, beta and gamma IFNs) is closely related to the first line of defenses against viral and tumoral diseases. Chronic leukemic and chronic lymphoproliferative patients respond in variable degrees to therapy with exogenous IFN. Remission after treatment with IFN-alpha in hairy cell leukemia (HCL) and in chronic myelogenous leukemia (CML) have been reported by other authors. In order to determine whether there are differences in IFN-alpha and beta genes between healthy and chronic leukemic individuals and among the different chronic leukemic patients, restriction fragment length polymorphism (RFLP) analyses was performed in a panel of patients with HCL, CML and chronic lymphocytic leukemia (CLL), and in a sample of healthy individuals. A significant difference in the allelic frequencies for the IFN-beta and Sst I enzyme in Chronic leukemias, mainly of myeloid origin, compared with the healthy individuals, was found.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Alleles
  • DNA Probes
  • Deoxyribonucleases, Type II Site-Specific
  • Female
  • Humans
  • Interferon-alpha / genetics*
  • Interferon-beta / genetics*
  • Interferon-gamma / genetics*
  • Leukemia, Hairy Cell / genetics*
  • Leukemia, Hairy Cell / immunology
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology
  • Male
  • Middle Aged
  • Polymorphism, Restriction Fragment Length*
  • Reference Values
  • Restriction Mapping

Substances

  • DNA Probes
  • Interferon-alpha
  • Interferon-beta
  • Interferon-gamma
  • endodeoxyribonuclease SacI
  • Deoxyribonucleases, Type II Site-Specific